Tham khảo bài thuyết trình những nghiên cứu về rối loạn chuyển hóa lipid, khoa học tự nhiên, công nghệ sinh học phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | NHÖÕNG NGHIEÂN CÖÙU VEÀ ROÁI LOAÏN CHUYEÅN HOAÙ LIPID GS. TSKH. Nguyeãn Maïnh Phan Chuû tòch Hoäi tim maïch TP. Hoà Chí Minh QUAÙ TRÌNH XÔ VÖÕA ÑOÄNG MAÏCH Figure 101 Statins also have similar effects to fibrates in relation to endothelial dysfunction, thrombogenicity and vascular inflammation. KW: statin, HMG-CoA reductase inhibitor, PPAR alpha, fibrate Caùc beänh lyù gaây RL chuyeån hoaù Lipid RLCH Lipid maùu nguyeân phaùt: Di truyeàn. RLCH Lipid maùu thöù phaùt do: Tieåu ñöôøng. Suy tuyeán yeân. Suy giaùp traïng. Hoäi chöùng thaän hö. Do duøng thuoác Khoâng trieäu chöùng + trieäu chöùng Quaù trình dieãn tieán cuûa xô vöõa ñoäng maïch: TG (naêm) Coù trieäu chöùng Sang thöông tieán trieån Beänh maïch vaønh Beänh maïch maùu naõo Beänh maïch maùu ngoaïi bieân Schematic time course of human atherogenesis In this timeline of atherosclerosis, note the compensatory enlargement as intimal thickening progresses, until later in the disease when luminal obstruction occurs. Keywords: . | NHÖÕNG NGHIEÂN CÖÙU VEÀ ROÁI LOAÏN CHUYEÅN HOAÙ LIPID GS. TSKH. Nguyeãn Maïnh Phan Chuû tòch Hoäi tim maïch TP. Hoà Chí Minh QUAÙ TRÌNH XÔ VÖÕA ÑOÄNG MAÏCH Figure 101 Statins also have similar effects to fibrates in relation to endothelial dysfunction, thrombogenicity and vascular inflammation. KW: statin, HMG-CoA reductase inhibitor, PPAR alpha, fibrate Caùc beänh lyù gaây RL chuyeån hoaù Lipid RLCH Lipid maùu nguyeân phaùt: Di truyeàn. RLCH Lipid maùu thöù phaùt do: Tieåu ñöôøng. Suy tuyeán yeân. Suy giaùp traïng. Hoäi chöùng thaän hö. Do duøng thuoác Khoâng trieäu chöùng + trieäu chöùng Quaù trình dieãn tieán cuûa xô vöõa ñoäng maïch: TG (naêm) Coù trieäu chöùng Sang thöông tieán trieån Beänh maïch vaønh Beänh maïch maùu naõo Beänh maïch maùu ngoaïi bieân Schematic time course of human atherogenesis In this timeline of atherosclerosis, note the compensatory enlargement as intimal thickening progresses, until later in the disease when luminal obstruction occurs. Keywords: atherogenesis Caùc thaønh phaàn Lipid Phaân loaïi roái loaïn chuyeån hoaù lipid (theo Friedrickson) Phaân loaïi roái loaïn chuyeån hoaù Lipid theo laâm saøng Taêng Cholesterol ñôn thuaàn: Type IIA Taêng Tryglyceride ñôn thuaàn: Type IV Taêng hoãn hôïp Cholesterol + Tryglyceride: Type IIB Caùc tyùp khaùc ( theo Friedrickson ít gaëp). 1970s 1988 Söï phaùt trieån cuûa khuyeán caùo ñieàu trò roái loaïn lipid maùu NCEP-ATP: 1993 2001 ATP I ATP II ATP III Framingham MRFIT LRC-CPPT Coronary Drug Project Helsinki Heart Study CLAS Angiographic Trials (FATS, POSCH, SCOR, STARS, Ornish, MARS) Meta-Analyses (Holme, Rossouw) 4S, WOSCOPS, CARE, LIPID, AFCAPS/TexCAPS, VA-HIT, others 2004 ATP III Update Allhat, ProveIT, ASCOT LLA, HPS Evolution of the NCEP guidelines To enhance the understanding and awareness regarding the risks of hyperlipidemia and to help guide physicians as to how to reduce this cardiovascular risk, the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) .
